Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
123 studies found for:    CARCINOID TUMORS, INTESTINAL
Show Display Options
Rank Status Study
1 Not yet recruiting Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
Condition: Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)
Intervention: Biological: blood sample withdrawn
2 Unknown  An Investigation of Small Intestinal Carcinoid Carcinoma in Families
Condition: Carcinoid Carcinoma
Intervention:
3 Withdrawn Randomized Phase III of PRRT Versus Interferon
Condition: Gastro-intestinal Neuroendocrine Tumors
Interventions: Drug: Interferon alpha-2b;   Drug: 177Lu-DOTATATE
4 Active, not recruiting A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Conditions: Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions: Drug: Octreotide LAR;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
5 Recruiting The MetNET-2 Trial
Condition: Neuroendocrine Tumors
Intervention: Drug: Lanreotide and Metformin
6 Completed Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
Conditions: Colorectal Cancer;   Constipation, Impaction, and Bowel Obstruction;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Gastrointestinal Stromal Tumor;   Quality of Life;   Small Intestine Cancer
Interventions: Procedure: bowel obstruction management;   Procedure: quality-of-life assessment
7 Recruiting A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Condition: Gastroenteropancreatic Neuroendocrine Tumor
Intervention: Drug: Famitinib
8 Terminated Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Drug: Gallium-68-DOTATATE PET/CT (index test);   Drug: Indium-111-Octreoscan (standard test)
9 Completed TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
Condition: Patients With Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 68-Ga-DOTANOC
10 Recruiting Community-based Neuroendocrine Tumor (NET) Research Study
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention:
11 Withdrawn Pasireotide Treatment for Neuroendocrine Tumor
Condition: Gastro-enteropancreatic Neuroendocrine Tumor
Interventions: Drug: Pasireotide;   Drug: Diazoxide
12 Active, not recruiting Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours
Condition: Gastroenteropancreatic Neuroendocrine Tumours
Intervention:
13 Not yet recruiting Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Conditions: Gastroenteropancreatic Neuroendocrine Tumor;   Lung Neuroendocrine Neoplasm
Intervention: Procedure: NETest
14 Recruiting 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: Intravenous injection of 177Lu-octreotate
15 Recruiting Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: 177Lu-DOTATATE 25.9 GBq activity;   Drug: 177Lu-DOTATATE 18.5 GBq activity
16 Not yet recruiting [68 Ga]-DOTANOC PET/CT in GEP-NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: [68Ga]-DOTANOC PET/CT
17 Active, not recruiting Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Drug: Lanreotide Autogel 120 mg;   Drug: Temozolomide (TMZ)
18 Not yet recruiting Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 in GEP NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 177Lu-OPS201
19 Completed 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 68Ga-OPS202
20 Recruiting 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Condition: Gastro-entero-pancreatic Neuroendocrine Tumors
Interventions: Drug: Capecitabine;   Drug: Lu-PRRT;   Drug: SS-LAR

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.